Cynosure develops and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure's product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ConBio brand names through a direct sales force in the United States, Canada, Mexico, France, Germany, Spain, the United Kingdom, Australia, China, Japan and Korea, and through international distributors in approximately 120 other countries.

Webcast ImageWebcast
Q2 2014 Cynosure Inc. Earnings Conference Call (Replay)
07/29/14 at 9:00 a.m. ET
Q2 2014 Cynosure Inc. Earnings Conference Call
Tuesday, July 29, 2014 9:00 a.m. ET  
Webcast PresentationHelp Help
Click here for webcast
CYNO (Common Stock)
ExchangeNASDAQ GS (US Dollar)
Price$22.44
Change (%) Stock is Down 0.3 (1.32%)
Volume397,696
Data as of 08/01/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote

News Releases

July 30, 2014
Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President
July 29, 2014
Cynosure Reports Second-Quarter 2014 Financial Results
July 24, 2014
Cynosure Receives Expanded FDA Clearance to Market PicoSure™ for Treatment of Acne Scars

Upcoming Events

There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.